• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 10, 2016

View Archived Issues

CMS takes aim at Part B drug prices, ups stakes in value-based debate

The Centers for Medicare & Medicaid Services (CMS) waded into the growing debate over the use of value-based pricing of prescription drugs by proposing to test a new model to deliver Medicare Part B drugs – infused cancer therapies, injectable antibiotics, eye care treatments and other treatments administered in a physician's office or hospital outpatient setting. Read More

EMA develops autism trial design guidelines

LONDON – Building on recent advances in understanding of the disease pathology, the EMA has for the first time formulated guidelines for companies developing treatments for autism, providing advice on inclusion criteria, trial design and choosing endpoints in this extremely heterogeneous disorder. Read More

Aprea raises $51M in series B for 1st-in-class p53-targeting APR-246

DUBLIN – Aprea AB raised €46 million (US$50.7 million) in a series B round that will fund a phase IIb trial in ovarian cancer of its first-in-class p53 reactivator APR-246, as well as a series of exploratory trials in several other oncology indications in which p53 mutations are implicated. The compound works by stabilizing the conformation of p53 proteins with point mutations in the DNA binding domain and has already generated promising clinical data as monotherapy and in combination with chemotherapy. Read More

WHO identifies key Zika R&D priorities for drugs, diagnostics

LONDON – A three-day meeting of drugs, vaccines and diagnostics experts convened by the World Health Organization (WHO) in Geneva this week has set out the key R&D priorities for developing products to combat the escalating Zika virus epidemic. Read More

Metabolic alterations may be targetable in TNBC

Scientists have discovered that triple-negative breast cancer (TNBC) that are driven by overexpression of the oncogene Myc have changes to their metabolism that can be targeted with inhibitors of fatty acid oxidation. Read More

Warren: No chance for Senate innovation bill without NIH funding

A Senate committee met to mark up legislation responding to the House 21st Century Cures bill passed last year, but Sen. Elizabeth Warren (D-Mass.) advised the GOP committee members that the legislation has little chance of passage on the Senate floor without mandatory funding for the NIH. Read More

Mayo, UCSF moving pharmacogenomics to front-line care

Two major medical centers chasing some of the multi-faceted rewards of genomic sequencing – better informed prescribing decisions and potentially lower medical costs – are making slow but steady strides in rolling out nascent infrastructures for the project, according to key players in the initiatives who spoke at the Molecular Medicine Tri-Con meeting this week. Read More

Financings

Stemcells Inc., of Newark, Calif., said it priced an underwritten public offering of common stock, series A warrants and series B warrants with an offering price of $0.30 for one share, a series A warrant to purchase 0.50 of a share of common stock and a series B warrant to purchase 0.75 of a share of common stock. Read More

Other news to note

Marathon Pharmaceuticals LLC, of Northbrook, Ill., said that it is expanding patient access to deflazacort, its investigational medicine for Duchenne muscular dystrophy (DMD) by making it available to qualified patients, at no cost, through a growing network of medical research centers across the country. Read More

In the clinic

Helix Biopharma Corp., of Aurora, Ontario, said Polish regulators approved an amendment to the phase I/II study (LDOS002) defining the dose and dosing regimen for the phase II portion. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe